Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
28
XTLB Quote, Financials, Valuation and Earnings
Last price:
$0.78
Seasonality move
:
-7.42%
Day range:
$0.74 - $0.80
52-week range:
$0.53 - $2.57
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.79x
P/B ratio:
1.26x
Volume:
8.4K
Avg. volume:
84.7K
1-year change:
-44.74%
Market cap:
$6.8M
Revenue:
$453.1K
EPS (TTM):
-$0.20
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, XTL Biopharmaceuticals Ltd. has 3770.97% upside to fair value with a price target of -- per share.
XTLB vs. S&P 500
-
Over the past 5 trading days, XTL Biopharmaceuticals Ltd. has underperformed the S&P 500 by -1.79% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
XTL Biopharmaceuticals Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
XTL Biopharmaceuticals Ltd. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter XTL Biopharmaceuticals Ltd. reported revenues of $162K.
Earnings Growth
-
XTL Biopharmaceuticals Ltd. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter XTL Biopharmaceuticals Ltd. reported earnings per share of -$0.16.
Enterprise value:
5.8M
EV / Invested capital:
--
Price / LTM sales:
13.79x
EV / EBIT:
50.25x
EV / Revenue:
12.85x
PEG ratio (5yr expected):
-0.20x
EV / Free cash flow:
-2.35x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
50.25x
Gross Profit (TTM):
--
Return On Assets:
-26.81%
Net Income Margin (TTM):
--
Return On Equity:
-34.34%
Return On Invested Capital:
-33.97%
Operating Margin:
-471.61%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $453.3K | -- | $291.3K | |
| Gross Profit | -- | -- | $2.7K | -- | -$43.3K | |
| Operating Income | -$880K | -$765K | -$2.2M | -$200K | -$818.5K | |
| EBITDA | -$1.3M | -$1.8M | -$1.1M | -- | -$479K | |
| Diluted EPS | -$0.33 | -$0.33 | -$0.11 | -$0.05 | -$0.03 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.1M | $6.2M | $3.8M | $2M | $1.3M | |
| Total Assets | $6.5M | $6.6M | $4.2M | $2.4M | $8.6M | |
| Current Liabilities | $254K | $231K | $187K | $206K | $2.2M | |
| Total Liabilities | $2.9M | $1.3M | $187K | $206K | $3.1M | |
| Total Equity | $3.6M | $5.3M | $4M | $2.2M | $5.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2012-12-31 | 2013-12-31 | 2014-12-31 | 2013-12-31 | 2014-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.5M | -$2.5M | -$2.5M | -$520K | -$674K | |
| Cash From Investing | -$1.2M | $3.3M | $1.5M | -$945K | $516K | |
| Cash From Financing | $4.3M | $317K | $309K | $172K | -- | |
| Free Cash Flow | -$1.6M | -$2.6M | -$2.5M | -$521K | -$674K | |
XTLB
Sector
Market Cap
$6.8M
$25.3M
Price % of 52-Week High
30.16%
49.41%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.6%
1-Year Price Total Return
-44.74%
-17.71%
Beta (5-Year)
1.193
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.80
200-day SMA
Sell
Level
$1.13
Bollinger Bands (100)
Sell
Level
0.72 - 1.18
Chaikin Money Flow
Buy
Level
219.1K
20-day SMA
Sell
Level
$0.88
Relative Strength Index (RSI14)
Sell
Level
41.28
ADX Line
Sell
Level
38.44
Williams %R
Neutral
Level
-70.3704
50-day SMA
Sell
Level
$0.85
MACD (12, 26)
Buy
Level
0.21
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Sell
Level
-14.9K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-23.5083)
Sell
CA Score
(Annual)
Level (-1.3196)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.4421)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Stock Forecast FAQ
In the current month, XTLB has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XTLB average analyst price target in the past 3 months is --.
-
Where Will XTL Biopharmaceuticals Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that XTL Biopharmaceuticals Ltd. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About XTL Biopharmaceuticals Ltd.?
Analysts are divided on their view about XTL Biopharmaceuticals Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that XTL Biopharmaceuticals Ltd. is a Sell and believe this share price will drop from its current level to --.
-
What Is XTL Biopharmaceuticals Ltd.'s Price Target?
The price target for XTL Biopharmaceuticals Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XTLB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for XTL Biopharmaceuticals Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of XTLB?
You can purchase shares of XTL Biopharmaceuticals Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase XTL Biopharmaceuticals Ltd. shares.
-
What Is The XTL Biopharmaceuticals Ltd. Share Price Today?
XTL Biopharmaceuticals Ltd. was last trading at $0.78 per share. This represents the most recent stock quote for XTL Biopharmaceuticals Ltd.. Yesterday, XTL Biopharmaceuticals Ltd. closed at $0.78 per share.
-
How To Buy XTL Biopharmaceuticals Ltd. Stock Online?
In order to purchase XTL Biopharmaceuticals Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get XTLB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
XTLB
Sector
P/E ratio
--
22.85x
PEG ratio
-0.20x
-0.01x
P/B ratio
1.26x
1.78x
Price / LTM sales
13.79x
1.52x
Growth Metrics
XTLB
Sector
Revenue growth
--
3.33%
Earnings growth
--
11.64%
Revenue (5-year growth)
--
6.41%
Earnings forecast
--
-$0.20
Profitability
XTLB
Sector
Profitability FY 2024
-$196.9K
$2.3M
Return on invested capital
-33.97%
-33.31%
Return on assets
-26.81%
-29.79%
Return on equity
-34.34%
-38.98%
Earnings Date
Last Earnings Date
Mar
5
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Jun
4
Balance Sheet
XTLB
Sector
Total cash
$1.7M
$24.1M
Short term investments
$772K
$23.8M
Total assets
$8.6M
$70.1M
Long term debt
$168K
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
